ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
ArriVent announced publication of FURTHER Phase 1b results for firmonertinib in Cancer Cell, supporting its potential as the first oral, chemotherapy-free targeted therapy for treatment-naive advanced EGFR PACC-mutant NSCLC. The data showed confirmed ORRs of 43% (160 mg) and 68% (240 mg) with median PFS of 11.1 and 16.0 months by BICR, plus 47% intracranial ORR in patients with baseline brain metastases.
Key figures
- Drug Name
- firmonertinib
- Phase Of Trial
- Phase 1b (FURTHER / FURMO-002)
- Orr 160mg
- 43%
- Orr 240mg
- 68%
- Next trial
- Phase 3 ALPACCA (FURMO-006; NCT07185997) vs osimertinib or afatinib
- Intracranial orr
- 47% (8/17)
- Median pfs months
- 11.1 (160mg) and 16.0 (240mg) by BICR
- Intracranial cr rate
- 41% among 17 patients with baseline brain metastases
- Pacc share of egfr mutations
- approximately 12%
- Ctdna complete molecular response
- 80% by cycle 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.